デフォルト表紙
市場調査レポート
商品コード
1603606

胃不全麻痺治療薬市場レポート:動向、予測、競合分析 (2030年まで)

Gastroparesis Drug Market Report: Trends, Forecast and Competitive Analysis to 2030


出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.06円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

胃不全麻痺治療薬市場レポート:動向、予測、競合分析 (2030年まで)
出版日: 2024年11月25日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

胃不全麻痺治療薬の動向と予測

世界の胃不全麻痺治療薬市場は、糖尿病性胃不全麻痺、特発性胃不全麻痺、手術後胃不全麻痺の各市場における機会により、将来性が期待されます。世界の胃不全麻痺治療薬市場は、2024年から2030年にかけてCAGR 4.5%で成長すると予想されます。この市場の主な促進要因は、手術件数の増加、糖尿病人口の罹患率の上昇、吐き気や嘔吐などの症状を管理するために設計された革新的な薬の発売です。

  • Lucintel社は、薬剤クラス別では制吐剤が予測期間中に最も高い成長を遂げると予測しています。
  • 疾患の種類別では、特発性胃不全麻痺が引き続き最大セグメントです。
  • 地域別では、高齢化人口の急増と外科手術件数の増加により、北米が予測期間中に最も高い成長を示すと予想されます。

胃不全麻痺治療薬市場の戦略的成長機会

本市場における主要な戦略的機会には、以下のようなものがあります:

  • 新薬開発への投資:新薬開発への投資:胃不全麻痺の様々なメカニズムを標的とした新薬の創出は、大幅な成長率をもたらす可能性があります。アンメットニーズを満たし、より良い治療法を提供するためには、薬剤設計と作用機序にイノベーションを集中させる必要があります。
  • 新興市場への進出:より多くの人々が胃不全麻痺と診断され、胃不全麻痺に対する認識が高まっている新興市場において、より多くの胃不全麻痺治療薬を提供することで、大きな成長の可能性があります。地域の嗜好に合わせて治療をローカライズすることで、より広い市場機会を獲得することができます。
  • デジタルヘルス技術の統合:製薬会社とモバイルヘルス企業の提携は、胃不全麻痺患者の予後を改善するための複合モニタリング・プラットフォームの開発に役立っています。この統合によりアドヒアランスが向上すると同時に、デジタルプラットフォームを使って個別化された治療法を処方する際に重要なデータが臨床医に提供されます。
  • 併用療法の開発:既存の治療と新薬や非薬理学的介入を統合する併用療法に焦点を当てることで、胃不全麻痺の包括的な管理が可能となります。このアプローチは様々な症状に対応し、全体的な治療効果を向上させることができます。
  • 個別化医療アプローチ:遺伝子プロファイリングやオーダーメイド治療を含む個別化医療戦略に投資することで、個々の患者に対する治療を最適化することができます。パーソナライズド・アプローチは、より良い治療結果をもたらし、市場における製品の差別化につながります。

結論として、これらの戦略的成長機会は、胃不全麻痺治療薬業界におけるイノベーションと市場拡大の可能性を浮き彫りにするものです。新しい技術やアプローチを活用することで、将来の成長を促進し、患者のケアを向上させることができます。

胃不全麻痺治療薬市場の促進要因・課題

胃不全麻痺治療薬市場は、その成長と発展に影響を与える様々な促進要因・課題の影響を受けています。これらの要因を理解することは、市場をナビゲートし、機会を活かすために極めて重要です。

胃不全麻痺薬市場を牽引する要因は以下の通りです:

  • 胃不全麻痺の有病率の増加:糖尿病やその他の基礎疾患に起因する胃不全麻痺の有病率の上昇が、効果的な治療に対する需要を促進しています。認知度の高まりと診断が市場ニーズの増加に寄与しています。
  • 薬剤研究の進歩:新規治療や製剤の改良など、医薬品研究開発の革新が治療の選択肢を広げています。これらの進歩はアンメットニーズに対応し、有効性を高めることで市場の成長を促進します。
  • デジタルヘルス技術の拡大:胃不全麻痺のモニタリングと管理のためのデジタルヘルスツールの統合は、患者のケアを向上させています。これらの技術はリアルタイムの症状追跡や治療調整を容易にし、市場の成長を支えています。
  • 新規治療に対する規制支援:規制プロセスの合理化と新薬承認のサポートにより、新規治療法のイントロダクションが促進されています。市場アクセスの改善と承認の迅速化が、胃不全麻痺治療薬市場の成長を促進しています。

胃不全麻痺治療薬市場における課題は以下の通りです:

  • 高い開発コスト:研究開発、臨床試験、承認取得など、胃不全麻痺治療薬の開発コストは高額になる可能性があります。高い開発コストは新規参入を減少させ、市場力学を変化させる可能性があります。
  • 限られた患者数:胃不全麻痺は他の疾患と比較して比較的稀であるため、新薬の市場規模が制限される可能性があります。患者数が少ないため、新薬開発への投資は企業にとって最適なリターンをもたらさない可能性があります。
  • 治療反応のばらつき:胃不全麻痺の治療に対する患者の反応の違いは、一貫した治療成績を達成する上で課題となりうる。患者間で治療効果にばらつきがあると、より広い市場での受容性に影響を与え、患者の満足度に影響を及ぼす可能性があります。
  • 規制上のハードル:複雑な規制要件を乗り越え、新たな治療法の承認を得ることは困難です。厳しい規制や長い承認プロセスは、新治療法のイントロダクションを遅らせる可能性があります。

結論として、これらの促進要因・課題は胃不全麻痺治療薬市場の複雑さを物語っています。これらの要因に対処する利害関係者は、この市場をうまく立ち回り、成長とイノベーションの機会を活用することができると思われます。

目次

第1章 エグゼクティブサマリー

第2章 世界の胃不全麻痺治療薬市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 市場動向と予測分析 (2018年~2030年)

  • マクロ経済動向 (2018~2023年) と予測 (2024~2030年)
  • 世界の胃不全麻痺治療薬市場の動向 (2018~2023年) と予測 (2024~2030年)
  • 世界の胃不全麻痺治療薬市場:薬剤クラス別
    • 消化管運動促進剤
    • 制吐剤
    • ボツリヌス毒素注射
  • 世界の胃不全麻痺治療薬市場:疾患の種類別
    • 糖尿病性胃不全麻痺
    • 特発性胃不全麻痺
    • 術後胃不全麻痺
    • その他
  • 世界の胃不全麻痺治療薬市場:流通チャネル別
    • 病院
    • 薬局
    • クリニック
    • eコマース

第4章 地域別の市場動向と予測分析 (2018年~2030年)

  • 世界の胃不全麻痺治療薬市場:地域別
  • 北米の胃不全麻痺治療薬市場
  • 欧州の胃不全麻痺治療薬市場
  • アジア太平洋の胃不全麻痺治療薬市場
  • その他地域の胃不全麻痺治療薬市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 運用統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 世界の胃不全麻痺治療薬市場の成長機会:薬剤クラス別
    • 世界の胃不全麻痺治療薬市場の成長機会:疾患の種類別
    • 世界の胃不全麻痺治療薬市場の成長機会:流通チャネル別
    • 世界の胃不全麻痺治療薬市場の成長機会:地域別
  • 世界の胃不全麻痺治療薬市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の胃不全麻痺治療薬市場の生産能力拡大
    • 世界の胃不全麻痺治療薬市場における企業合併・買収 (M&A)、合弁事業
    • 認証とライセンシング

第7章 主要企業のプロファイル

  • Allergan
  • Abbott Laboratories
  • AstraZeneca
  • Cadila Pharmaceuticals
  • ETX Pharma
  • Evoke Pharma
  • GlaxoSmithKline
目次

Gastroparesis Drug Trends and Forecast

The future of the global gastroparesis drug market looks promising with opportunities in the diabetic gastroparesis, idiopathic gastroparesis, and post-surgical gastroparesis markets. The global gastroparesis drug market is expected to grow with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are an increase in the number of surgeries, a rising incidence rate of the diabetic population, and the launch of innovative medications designed to manage symptoms like nausea and vomiting.

  • Lucintel forecasts that, within the drug class category, antiemetic agents are expected to witness the highest growth over the forecast period.
  • Within the disease type category, idiopathic gastroparesis will remain the largest segment.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to a surge in the aging population, along with an increasing number of surgical procedures.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Gastroparesis Drug Market

Emerging trends in the gastroparesis drug market are reshaping its future applications and dynamics. Key trends include:

  • Novel Therapeutics: New drugs targeting different mechanisms of gastroparesis are being developed. These include agents that address motility disorders more effectively and offer improved symptom management compared to current treatments.
  • Extended-Release Formulations: The development of extended-release drug formulations from existing gastroparesis drugs has become a growing trend. The objective of these formulations is to provide sustained relief from symptoms by reducing the frequency of dosing, thus enhancing patient adherence.
  • Combination Therapies: Combining existing drugs with new agents or therapies is becoming more common. This approach aims to enhance overall efficacy and manage symptoms more comprehensively by addressing multiple pathways involved in gastroparesis.
  • Personalized Medicine: The use of genetic and biomarker information to individualize gastroparesis treatments has gained traction. Personalized approaches aim to optimize therapy based on specific patient characteristics, improving treatment outcomes.
  • Digital Health Integration: With the increased focus on the future of digital health, app-based technologies and gadgets like wearables are now being used to manage symptoms of gastroparesis and ensure medication compliance. These technologies provide dynamic data and allow for more personalized treatment.

In conclusion, these emerging trends reflect significant advancements in the gastroparesis drug market, focusing on novel therapies, personalized medicine, and innovative delivery methods. These developments aim to enhance treatment efficacy and patient outcomes, driving future growth in the industry.

Recent Developments in the Gastroparesis Drug Market

Ongoing innovations and advancements in the gastroparesis drug market have been highlighted by recent developments:

  • Approval of New Medications: In recent years, a number of drugs have been approved for treating gastroparesis, including specialized motility agents. These drug types use different mechanisms of action, offering alternatives for patients who do not respond positively to conventional treatments. These drugs are anticipated to greatly improve overall management and outcomes for people suffering from gastroparesis.
  • Enhanced Formulations of Existing Drugs: One example is long-acting or controlled-release formulations, which reduce dosing frequency, thus improving patient compliance while enhancing symptom control efficacy. Through this approach, symptoms last longer, meaning fewer doses are necessary, making it easier for patients to follow their treatment regimens.
  • Emergence of Digital Health Solutions: Technological advancements, such as mobile apps and portable gadgets, have taken gastroparesis management in a new direction. These devices allow for real-time symptom tracking and facilitate timely medication intake adjustments based on the findings from these digital health tools. Additionally, the inclusion of digital health solutions makes communication easier between patients and healthcare providers.
  • Increased Focus on Combination Therapies: Some researchers are investigating how they can combine traditional drug treatments with new drugs or even non-pharmacological remedies. By doing so, multiple aspects of gastroparesis can be addressed at once, improving overall symptom control as well as patient outcomes. Consequently, clinical tests have been launched to examine whether these combinations indeed boost treatment efficacy.

In summary, these recent developments reflect a significant evolution in the gastroparesis drug market, emphasizing new medications, improved formulations, and innovative digital health solutions. These advancements are poised to enhance patient care and expand treatment options.

Strategic Growth Opportunities for Gastroparesis Drug Market

Some key strategic opportunities in this market include:

  • Investment in Novel Drug Development: Creating new drugs targeted at varying gastroparesis mechanisms could result in substantial growth rates. Innovation should focus on drug design and mechanisms of action to meet unmet needs and offer better treatments.
  • Expansion into Emerging Markets: There is substantial growth potential through making more products available to treat gastroparesis in emerging markets, where more people are being diagnosed, and awareness of the condition is increasing. Localizing treatments to meet regional preferences can open up wider market opportunities.
  • Integration of Digital Health Technologies: Partnerships between pharmaceutical companies and mobile health firms are helping to develop combined monitoring platforms to improve outcomes for gastroparesis patients. This integration will improve adherence while providing clinicians with vital data when prescribing personalized therapies using digital platforms.
  • Development of Combination Therapies: Focusing on combination therapies that integrate existing treatments with new drugs or non-pharmacological interventions can provide comprehensive management of gastroparesis. This approach can address various symptoms and improve overall treatment efficacy.
  • Personalized Medicine Approaches: Investing in personalized medicine strategies, including genetic profiling and tailored treatments, can optimize therapy for individual patients. Personalized approaches can lead to better outcomes and differentiate offerings in the market.

In conclusion, these strategic growth opportunities highlight the potential for innovation and market expansion in the gastroparesis drug industry. Leveraging new technologies and approaches can drive future growth and improve patient care.

Gastroparesis Drug Market Driver and Challenges

The gastroparesis drug market is influenced by various drivers and challenges that affect its growth and development. Understanding these factors is crucial for navigating the market and capitalizing on opportunities.

The factors responsible for driving the gastroparesis drug market include:

  • Increasing Prevalence of Gastroparesis: The rising prevalence of gastroparesis, driven by factors such as diabetes and other underlying conditions, is fueling demand for effective treatments. Growing awareness and diagnosis are contributing to increased market needs.
  • Advancements in Drug Research: Innovations in drug research and development, including novel therapies and improved formulations, are expanding treatment options. These advancements address unmet needs and enhance efficacy, driving market growth.
  • Expansion of Digital Health Technologies: The integration of digital health tools for monitoring and managing gastroparesis is improving patient care. These technologies facilitate real-time symptom tracking and treatment adjustments, supporting market growth.
  • Regulatory Support for New Treatments: Streamlined regulatory processes and support for new drug approvals are facilitating the introduction of novel therapies. Improved market access and faster approvals are driving growth in the gastroparesis drug market.

Challenges in the gastroparesis drug market are:

  • High Development Costs: The cost of developing new gastroparesis drugs, including research, clinical trials, and regulatory approvals, can be high. High development costs may reduce new entrants and alter market dynamics.
  • Limited Patient Population: Gastroparesis is relatively rare compared to other conditions, which can limit the market size for new drugs. Investment in drug development may not provide optimal returns for companies, as the number of patients is small.
  • Variability in Treatment Response: Differences in how patients respond to gastroparesis treatments can pose challenges in achieving consistent outcomes. Variations in treatment effectiveness among patients could affect its acceptance by the broader market and influence patient satisfaction.
  • Regulatory Hurdles: Navigating complex regulatory requirements and gaining approvals for new treatments can be challenging. Stringent regulations and lengthy approval processes may delay the introduction of new therapies.

In conclusion, these drivers and challenges illustrate the complexities of the gastroparesis drug market. Stakeholders addressing these factors will successfully navigate this market and take advantage of growth and innovation opportunities.

List of Gastroparesis Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies gastroparesis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gastroparesis drug companies profiled in this report include-

  • Allergan
  • Abbott Laboratories
  • AstraZeneca
  • Cadila Pharmaceuticals
  • ETX Pharma
  • Evoke Pharma
  • GlaxoSmithKline

Gastroparesis Drug by Segment

The study includes a forecast for the global gastroparesis drug by drug class, disease type, distribution channel, and region.

Gastroparesis Drug Market by Drug Class [Analysis by Value from 2018 to 2030]:

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Gastroparesis Drug Market by Disease Type [Analysis by Value from 2018 to 2030]:

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-Surgical Gastroparesis
  • Others

Gastroparesis Drug Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Pharmacies
  • Clinics
  • e-Commerce

Gastroparesis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Gastroparesis Drug Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. The following highlights recent developments by major gastroparesis drug producers in key regions: the USA, China, India, Japan, and Germany.

  • United States: The U.S. has recently seen several developments in gastroparesis drugs, including the approval of new medications and updated formulations for existing treatments. These advancements focus on improving patient adherence through the use of extended-release drug delivery systems, which help manage symptoms more effectively. Additionally, research is ongoing on the use of newer agents and combination therapies to achieve better outcomes while minimizing adverse effects.
  • China: China's gastroparesis drug market is evolving with the introduction of more affordable generic versions of established drugs. There is also growing interest in developing new treatments targeting the core symptoms of gastroparesis. Research institutions are focusing on localizing drug development to address specific regional needs and improve accessibility.
  • Germany: Germany has witnessed progress in treating gastroparesis, with innovations being integrated into clinical practices to improve patient access through health reforms. The country is also investing in research to gain deeper insights into the mechanisms underlying gastroparesis, including the development of targeted therapies that address patient specificity and optimize treatment effectiveness.
  • India: India's gastroparesis drug market continues to grow due to efforts focused on increasing the availability of affordable treatments. Research on generics and alternative formulations has been initiated to make treatments more accessible to a wider patient population. Additionally, initiatives aimed at raising awareness about gastroparesis and its diagnosis are contributing to improved management and treatment options.
  • Japan: In Japan, advancements in the gastroparesis drug market are being made through the introduction of new drugs and improvements in formulations for existing ones. This includes innovative drug delivery systems designed to optimize treatment efficacy while minimizing side effects. Japanese researchers are also exploring personalized treatments based on genetic and clinical data, aiming to optimize outcomes for patients diagnosed with gastroparesis.

Features of the Global Gastroparesis Drug Market

Market Size Estimates: Gastroparesis drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Gastroparesis drug market size by drug class, disease type, distribution channel, and region in terms of value ($B).

Regional Analysis: Gastroparesis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, disease types, distribution channels, and regions for the gastroparesis drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gastroparesis drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the gastroparesis drug market by drug class (prokinetic agents, antiemetic agents, and botulinum toxin injections), disease type (diabetic gastroparesis, idiopathic gastroparesis, post-surgical gastroparesis, and others), distribution channel (hospitals, pharmacies, clinics, and e-commerce), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Gastroparesis Drug Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Gastroparesis Drug Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Gastroparesis Drug Market by Drug Class
    • 3.3.1: Prokinetic Agents
    • 3.3.2: Antiemetic Agents
    • 3.3.3: Botulinum Toxin Injections
  • 3.4: Global Gastroparesis Drug Market by Disease Type
    • 3.4.1: Diabetic Gastroparesis
    • 3.4.2: Idiopathic Gastroparesis
    • 3.4.3: Post-surgical Gastroparesis
    • 3.4.4: Others
  • 3.5: Global Gastroparesis Drug Market by Distribution Channel
    • 3.5.1: Hospitals
    • 3.5.2: Pharmacies
    • 3.5.3: Clinics
    • 3.5.4: e-commerce

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Gastroparesis Drug Market by Region
  • 4.2: North American Gastroparesis Drug Market
    • 4.2.1: North American Market by Drug Class: Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections
    • 4.2.2: North American Market by Disease Type: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others
  • 4.3: European Gastroparesis Drug Market
    • 4.3.1: European Market by Drug Class: Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections
    • 4.3.2: European Market by Disease Type: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others
  • 4.4: APAC Gastroparesis Drug Market
    • 4.4.1: APAC Market by Drug Class: Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections
    • 4.4.2: APAC Market by Disease Type: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others
  • 4.5: ROW Gastroparesis Drug Market
    • 4.5.1: ROW Market by Drug Class: Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections
    • 4.5.2: ROW Market by Disease Type: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Gastroparesis Drug Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Gastroparesis Drug Market by Disease Type
    • 6.1.3: Growth Opportunities for the Global Gastroparesis Drug Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Gastroparesis Drug Market by Region
  • 6.2: Emerging Trends in the Global Gastroparesis Drug Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Gastroparesis Drug Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gastroparesis Drug Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Allergan
  • 7.2: Abbott Laboratories
  • 7.3: AstraZeneca
  • 7.4: Cadila Pharmaceuticals
  • 7.5: ETX Pharma
  • 7.6: Evoke Pharma
  • 7.7: GlaxoSmithKline